Quarterly Report January – March 2003

QUARTERLY REPORT january – march 2003

· A novel first-in-class compound for type 2 diabetes has been
identified in the collaboration with Abbott Pharmaceuticals.

· Significant progress made in the collaboration with Bristol-Myers
Squibb through the identification of novel and improved compound for
obesity treatment.

· Group net sales decreased to MSEK 12.7 (37.4).

· Cash flows from operating activities amounted to MSEK -39.7
(-38.7).

· Operating loss excluding goodwill amortization amounted to MSEK
42.0 (21.4). The loss after financial items, including goodwill
amortization, amounted to MSEK 100.4 (79.5).

· Cash and cash equivalents and short-term investments amounted to
MSEK 161.2 (241.9) at the end of the period.

· New share issue decided, expected to raise MSEK 120 if fully
subscribed.

For further information, please contact
Björn Nilsson, President & CEO tel. +46 8 608 60 20, Per Otteskog,
Senior Vice President, tel. +46 8 608 60 18, or Bertil Jungmar, Chief
Financial Officer, tel. +46 8 608 60 52.

————————————————————
This information was brought to you by Waymaker https://www.waymaker.net
The following files are available for download:
https://www.waymaker.net/bitonline/2003/04/23/20030423BIT00130/wkr0001.doc The full report
https://www.waymaker.net/bitonline/2003/04/23/20030423BIT00130/wkr0002.pdf The full report